Idorsia Ltd (SWX:IDIA)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.08B +304.7% |
| Revenue (ttm) | 219.10M +35.8% |
| Net Income | -220.51M |
| EPS | -0.96 |
| Shares Out | 255.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,183,592 |
| Open | 4.390 |
| Previous Close | 4.390 |
| Day's Range | 4.102 - 4.414 |
| 52-Week Range | 1.578 - 4.870 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 4.50 (+6.23%) |
| Earnings Date | Jul 30, 2026 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t... [Read more]
Financial Performance
In 2025, Idorsia's revenue was 220.58 million, an increase of 96.06% compared to the previous year's 112.51 million. Losses were -111.70 million, -57.65% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IDIA stock is "Buy." The 12-month stock price target is CHF 4.50, which is an increase of 6.23% from the latest price.
News
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
Allschwil, Switzerland – June 1, 2026 Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in ...
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRECISION study demonstrating that aprocitentan, Idorsia's dual endothelin receptor antagonist, s...
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
Allschwil, Switzerland – May 6, 2026 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Boa...
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Ad hoc announcement pursuant to Art. 53 LR Preparation is underway to publish the strong pediatric daridorexant data and engage with regulatory authorities on next steps Co-promotion of QUVIVIQ is bei...
Idorsia Quarterly report: Q1 2026
Idorsia has published its Q1 2026 quarterly earnings report on April 28, 2026.
Idorsia Earnings release: Q1 2026
Idorsia released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meetin...
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Developmen...
Idorsia Transcript: Study result
A phase II study in children with insomnia, including those with neurodevelopmental disorders, showed daridorexant significantly increased sleep time and improved morning alertness with a strong safety profile. The results suggest potential benefits beyond insomnia and support further regulatory discussions for pediatric and NDD indications.
Idorsia Press release: Study result
Idorsia issued a press release on March 31, 2026, disclosing material business information to investors.
Idorsia Slides: Study result
Idorsia has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
Idorsia announces the nomination of three candidates for election to the Board of Directors
Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of ...
Idorsia announces management change
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti wi...
Idorsia price target lowered to CHF 5 from CHF 6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Idorsia (IDRSF) to CHF 5 from CHF 6 and keeps a Buy rating on the shares. The firm cites reduced forward visibility…
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridor...
Idorsia Transcript: TD Cowen 46th Annual Health Care Conference
Restructured debt and strong commercial execution have positioned the company for growth, with Quviviq outperforming sales expectations and expanding globally. The pipeline advances with pivotal trials for lucerastat and new programs in dermatology and neurology, while partnership strategies aim to maximize asset value.
Idorsia Earnings Call Transcript: Q4 2025
2025 saw a turnaround with QUVIVIQ sales more than doubling and operating losses sharply reduced, driven by commercial execution and cost control. TRYVIO/JERAYGO gained regulatory traction, and the pipeline advanced with clear plans for Fabry disease and immunology assets.
Idorsia Earnings release: H2 2025
Idorsia released its H2 2025 earnings on February 26, 2026, summarizing the period's financial results.
Idorsia Annual report: H2 2025
Idorsia has published its H2 2025 annual report on February 26, 2026.
Idorsia Slides: H2 2025
Idorsia has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.
Idorsia Slides: Company presentation
Idorsia has posted slides in relation to its latest quarterly earnings report, which was published on February 26, 2026.
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Allschwil, Switzerland – January 30, 2026 Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORL...
Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd...